Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Revenue projections:

Revenue projections for NATCOPHARM
Revenue projections for NATCOPHARM

With NATCOPHARM's revenue forecasted to drop below last year's level, investors are expected to take a cautious stance. Such declines typically affect a company's bottom line, reducing profitability and making investors hesitant to invest heavily in the company until financial performance improves.

Financial Ratios:

currentRatio 3.006000
forwardPE 19.731441
debtToEquity 7.742000
earningsGrowth -0.341000
revenueGrowth -0.396000
grossMargins 0.830690
operatingMargins 0.104450
trailingEps 79.170000
forwardEps 45.800000

NATCOPHARM's current ratio 3.006, suggesting the company has sufficient liquidity to service its short-term debt. With its cash reserves and current assets in good shape, NATCOPHARM can comfortably meet its immediate liabilities, reflecting a healthy financial standing.
NATCOPHARM's Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
NATCO Pharma Limited's low growth in both earnings and revenue signals a potential profit decline. This could be a sign of financial trouble, suggesting that the company's profitability might shrink in the near future.
NATCO Pharma Limited's negative gross and operating margins indicate that the company is operating at a loss. This reflects an inability to cover production costs and operational expenses, which could undermine its financial stability.
NATCOPHARM's forward EPS being lower than trailing EPS indicates reduced profitability in the upcoming year. This points to a potential decline in earnings, which could impact the company's financial strength.

Price projections:

Price projections for NATCOPHARM
Price projections for NATCOPHARM

The price of NATCOPHARM has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for NATCOPHARM
Insider Transactions for NATCOPHARM


5 NATCOPHARM sales were executed, with market price at 906.7699951171875.NATCO Pharma Limited saw 1 buying transactions, each while market price hovered at 881.6500244140625.More sells than buys at NATCOPHARM's current price levels suggest potential weakness. If this trend continues, the stock may experience further price declines as selling pressure increases.

Recommendation changes over time:

Recommendations trend for NATCOPHARM
Recommendations trend for NATCOPHARM


Analysts have been favoring NATCOPHARM with a buy bias recently, signaling a promising investment opportunity. This optimistic outlook may attract more investors, positioning NATCOPHARM as a desirable option for those seeking to invest their money in a stable, profitable company with strong growth potential.